Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl and Lyn kinase. The patient exhibited a molecular response for CML and a partial response for CLL. To our knowledge, this is the first report to describe the occurrence of a gradual increase in the Bcr-Abl transcript level prior to the diagnosis of Ph-positive CML in an individual with CLL who was successfully treated with dasatinib as the first-line therapy.
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Takayo
T
Nagao
Naoto
N
Takahashi
Yoshihiro
Y
Kameoka
Shinsuke
S
Noguchi
Yoshinori
Y
Shinohara
Hideaki
H
Ohyagi
Masaaki
M
Kume
Kenichi
K
Sawada
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D025063:Chromosome Disorders / Q000235:genetics; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D000069439:Dasatinib; D005260:Female; D016313:Genes, abl; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib